orantinib has been researched along with hypericin in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (hypericin) | Trials (hypericin) | Recent Studies (post-2010) (hypericin) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 982 | 31 | 380 |
| Protein | Taxonomy | orantinib (IC50) | hypericin (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 8.7 | |
| Corticotropin-releasing factor receptor 1 | Homo sapiens (human) | 0.3 | |
| Cystathionine beta-synthase | Homo sapiens (human) | 3.1 | |
| Alpha-synuclein | Homo sapiens (human) | 7.5 | |
| Glutathione reductase | Saccharomyces cerevisiae S288C | 3.67 | |
| Integrase | Human immunodeficiency virus 1 | 10 | |
| Cysteine protease ATG4B | Homo sapiens (human) | 8.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chowbay, B; Lye, KY; Moore, S; Olivo, M; Sharma, A; Zhou, Q | 1 |
1 trial(s) available for orantinib and hypericin
| Article | Year |
|---|---|
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Gene Expression; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Oxindoles; Perylene; Photochemotherapy; Propionates; Protein-Tyrosine Kinases; Proteins; Pyrroles; Survival Rate | 2005 |